Advertisement

Organisation › Details
TxCell S.A. (Euronext Paris: TXCL)
TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, the TxCell's second drug candidate developed as a treatment for autoimmune uveitis, is expected to enter in clinical studies in the near future. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 47 employees. *
![]() |
Start | 2001-01-01 splitoff |
![]() |
End | 2024-12-31 closed (date ca.) |
Group | Sangamo (Group) | |
Today | Sangamo (Group) | |
Predecessor | Inserm (National Institute for Health and Medical Research, FR) | |
Successor | Sangamo (Group) | |
![]() |
Industry | ASTrIA technology (Antigen Specific Treg for Inflammation and Autoimmunity) |
Industry 2 | ENTrIA technology (Engineered Treg for Inflammation and Autoimmunity) | |
![]() |
Person | Boissel, Stéphane (SparingVision 202010– CEO before Sangamo + TxCell + Genclis + Transgene + Innate Pharma + Lazard) |
Person 2 | Flipo, Raphaël (TxCell 201509 CFO) | |
![]() |
Region | Valbonne |
Country | France | |
Street | Allée de la Nertière Les Cardoulines HT1 | |
City | 06560 Valbonne – Sophia Antipolis | |
Tel | +33-4-9721-8300 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2017-12-31) |
Currency | EUR | |
Annual sales | 2,234,000 (revenue + other income (2017) 2017-12-31) | |
Profit | -10,911,000 (2016-12-31) | |
Cash | 4,910,000 (2017-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-08-08 |
Advertisement

More documents for Sangamo (Group)
- [1] Sangamo Therapeutics, Inc.. (8/6/24). "Press Release: Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases". Richmond, CA....
- [2] MorphoSys AG. (1/6/21). "Press Release: MorphoSys Appoints Sung Lee as Chief Financial Officer". Planegg....
- [3] Mogrify Ltd.. (4/21/20). "Press Release: Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-derived Regulatory T Cells". Cambridge & Brisbane, CA....
- [4] Sangamo Therapeutics, Inc.. (11/19/19). "Press Release: Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation". Brisbane, CA....
- [5] Sangamo Therapeutics, Inc.. (11/18/19). "Press Release: Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference". Brisbane, CA....
- [6] Sangamo Therapeutics, Inc.. (11/1/19). "Press Release: Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer". Brisbane, CA....
- [7] Sangamo Therapeutics, Inc.. (7/31/19). "Press Release: Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel". Brisbane, CA....
- [8] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Announces Agreement Securing Access To Large-scale, Commercial-grade Manufacturing Capacity at Brammer Bio". Brisbane, CA....
- [9] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy". Brisbane, CA & New York, NY....
- [10] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data". Brisbane, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top